News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
Kelun-Biotech's Sacituzumab Tirumotecan and Two Other Cancer Drugs Selected for ASCO 2026 Oral Presentations
Kelun-Biotech announces three clinical studies selected for oral presentations at ASCO 2026, including TROP2 ADC sacituzumab tirumotecan results.
NOVI Health's Hybrid Care Model Bridges GLP-1 Drug Efficacy Gap Between Clinical Trials and Real-World Outcomes
NOVI Health introduces hybrid care approach to improve real-world GLP-1 obesity drug outcomes that typically underperform compared to clinical trials.
Duchesnay and PeriPharm Call for Regulatory Reform as Canadian Women Wait 3+ Years for Health Innovations
Duchesnay and PeriPharm publish joint study revealing Canadian women wait over three years to access new health treatments, calling for regulatory updates.
Australia's TGA Updates In Vitro Diagnostic Device Regulations for Medical Device Manufacturers
Australia's Therapeutic Goods Administration releases comprehensive guidance for in vitro diagnostic device manufacturing, applications, and market authorization.
Washington State Life Sciences Industry Leads National Growth for Fifth Consecutive Year, Contributing $24.4B to GDP
Washington's life sciences sector outpaces national growth for 5th year, contributing $24.4B to state GDP with third-largest AI specialist cluster in US.
PDA APAC: Pharma Manufacturing Trends in 2026
PDA's 2026 pharmaceutical manufacturing events in APAC will focus on technology, sterile products, packaging, and contamination control. Key events include the Visual Inspection Forum in Dublin and the Parenteral Packaging Conference in Munich.
ChinaBio Partnering Forum 2026: APAC Biotech Deals Preview
Preview of the ChinaBio Partnering Forum 2026, focusing on cross-border biotech/pharma partnering in China, taking place in Shanghai and virtually.
Suvoda Launches Agentic AI-Powered RTSM System, Reduces Clinical Trial Startup Time by 80%
Suvoda's new agentic RTSM uses AI to cut clinical trial startup timelines by up to 80%, accelerating drug development and patient access to treatments.
Dayspring Pharma's CG2001 Foam Meets Primary Endpoint in Phase II Male Pattern Baldness Trial
Dayspring Pharma announces positive Phase II results for CG2001 foam in treating male pattern baldness, showing significant efficacy in Chinese men.
MyOme Appoints Two Healthcare Leaders to Board as AI Genomics Platform Expands
MyOme strengthens its board with Sam Roosz and Dr. Ravi Thadhani appointments, bringing healthcare technology and clinical expertise to AI genomics platform.
SynbioTech's L. plantarum FS4722 Shows Promise for Hyperuricemia Prevention in Preclinical Studies
SynbioTech's probiotic strain L. plantarum FS4722 demonstrates potential for hyperuricemia prevention through gut-liver-kidney axis modulation in preclinical trials.
Global Nasal Sprays Market Projected to Reach $29.7 Billion by 2036 as Allergy Cases Rise
The global nasal sprays market will grow from $16.8 billion in 2026 to $29.7 billion by 2036, driven by rising allergic rhinitis cases and non-oral delivery preferences.
Andelyn Biosciences Partners with ENCell to Expand Gene Therapy Manufacturing in Asia-Pacific
Andelyn Biosciences and ENCell form strategic partnership to enhance global gene therapy manufacturing capabilities and expand access to treatments.
Turbine Partners with Crown Bioscience to Advance AI-Powered Cancer Drug Discovery Using Organoid Technology
Turbine and Crown Bioscience announce strategic partnership combining AI virtual screening with organoid tumor models to accelerate oncology research and drug development.
Australia's TGA Updates Medicinal Cannabis Access Guidelines for Pediatric Patients Under Special Access Scheme
Australia's TGA clarifies medicinal cannabis access requirements for pediatric patients under 18 through Special Access Scheme and Authorised Prescriber pathways.
Australia's TGA Updates Guidance for Accessing Unapproved Therapeutic Goods Through Special Access Scheme
Australia's TGA provides updated pathways for healthcare practitioners and consumers to access unapproved therapeutic goods not on the ARTG register.
GHIT Fund Invests $8.5 Million in Malaria and NTD Drug Development with GSK, Eisai Partners
GHIT Fund announces $8.5 million investment across five R&D projects for malaria and neglected tropical disease treatments with major pharma partners.
GHIT Fund Invests $8.5 Million in Malaria and Neglected Tropical Disease Drug Development with GSK, Eisai Partners
GHIT Fund announces $8.5M investment across five R&D projects targeting malaria and neglected tropical diseases with pharmaceutical partners.
PeptiDream Partner Asahi Kasei Therapeutics Initiates Phase 1 Clinical Trial for AK1940
Asahi Kasei Therapeutics begins Phase 1 clinical trial for AK1940, developed through collaboration with PeptiDream Inc., marking key milestone in drug development.
Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026
Rznomics reports encouraging interim data for RZ-001 RNA editing therapy in liver cancer, showing 61.5% response rate with favorable safety profile at AACR 2026.